MAPT and Alzheimer disease: As the Alzheimer’s disease research community has transitioned towards a biological definition of the disease,7 the emergence of anti-Aβ therapies approved by the Food and Drug Administration (FDA) and upcoming clinical trials emphasize the importance of validated blood biomarkers for detecting abnormal Aβ and tau pathology.